Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ozanimod

- PMLiVE

Biogen and Happify Health team up to create digital platform for MS patients

There are over 2.3 million people living with MS worldwide, with women being more likely to develop the condition than men

- PMLiVE

Innovative Trials partners with MS Society

UK-based patient recruitment company announces its annual charity partnership in support of multiple sclerosis

Innovative Trials

- PMLiVE

Biogen and MedRhythms sign deal worth over $120m for digital therapeutics for MS patients

The collaboration is focused on improving MS patients’ mobility and walking

Roche Basel Switzerland

Roche shares new positive Ocrevus data for MS patients

The CONSONANCE trial showed treatment with Ocrevus resulted in a majority of patients experiencing no disease progression

Biogen Idec building

SMC approves Biogen’s Vumerity for patients with multiple sclerosis

The new, at-home oral treatment has been developed for adults in Scotland living with relapsing-remitting multiple sclerosis

- PMLiVE

Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS

The data presented at ECTRIMS 2021 reinforces the efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis

Sanofi reception

Sanofi’s tolebrutinib demonstrates favourable one-year tolerability in patients with relapsing forms of multiple sclerosis

New long-term data presented at ECTRIMS 2021 reinforces promising safety and efficacy profile

Biogen Idec building

Data shows patients treated with Biogen’s MS therapies mount an effective antibody response to COVID-19 vaccination

New MS PATHS data was presented at ECTRIMS 2021

Biogen Idec building

Biogen’s Vumerity recommended by CHMP in MS

A thumbs up for Vumerity in the EU could ease the way for Biogen’s follow-up to Tecfidera in multiple sclerosis

Biogen Idec building

Biogen pays InnoCare $125m upfront for potential multiple sclerosis treatment

Orelabrutinib is currently being evaluated in a phase 2 trial in relapsing-remitting MS

Sanofi reception

Sanofi’s oral therapy Aubagio approved in the EU for paediatric MS patients

EC approval comes a few weeks after the FDA rejected Aubagio in the same patient population

- PMLiVE

BMS’ Zeposia gains FDA approval in ulcerative colitis

Treatment was initially approved in 2020 for multiple sclerosis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links